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The fine needle aspiration (FNA) test is a convenient and tolerable technique with minimal invasion that is accepted by most 
women. Local estrogen synthesis depends mainly on the aromatase and steroid sulfatase pathways that are believed to play im-
portant roles in breast carcinogenesis. However, little is known about the level of aromatase and steroid sulfatase mRNA expres-
sion in FNA samples which contain only small amounts of tissue. The nested Q-PCR assay has been proven to be a highly sensi-
tive and specific method to assess the aromatase expression of breast tissue. In this study, aromatase and steroid sulfatase mRNA 
expression in 74 patients with benign or malignant disorders was evaluated and compared using nested Q-PCR and non-nested 
Q-PCR assays. The expression levels were analyzed and correlated with clinical parameters. No difference in the aromatase ex-
pression levels between nested and non-nested Q-PCR was noticed. Age and aromatase mRNA expression level were two inde-
pendent risk factors for breast cancer (P=0.04 and P=0.00, respectively), while menopausal status and steroid sulfatase mRNA 
expression levels were not associated with breast cancer. This study showed that both nested and non-nested Q-PCR assays were 
effective methods for research using FNA breast samples. 
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A variety of evidence suggests that estrogen is critical in 
breast carcinogenesis [1–3]. Intratumoral estrogen concen-
trations in breast cancer are much higher than in plasma, 
especially in postmenopausal women, indicating that local 
estrogen production might be a major contributor [4]. The 
difference between plasma and tissue estrogen levels may 
be caused by the aromatase and sulfatase enzymes that are 
active in two local estrogen biosynthesis pathways in breast 
tissue [5]. Aromatase and steroid sulfatase expressions were 
considered as markers of endocrine responsiveness which 
may have prognostic implications for breast cancer progres-
sion [6]. 
Recently, fine needle aspiration (FNA) has been used for 
cytological assessment and identification of surrogate mo-
lecular markers. This method might also aid in predicting 
breast cancer risk and treatment response [7]. A screening 
method using this technique would make it possible to in-
vestigate normal or pre-malignant breast tissue. Because of 
a very small amount of breast tissue obtained by FNA, the 
challenge is to develop a method that is sensitive and spe-
cific enough to detect the mRNA expression levels of aro-
matase and steroid sulfatase. Previously, we established a 
nested Q-PCR assay for human aromatase and successfully 
analyzed several ductal lavage fluid samples [8]. 
In the present study, both aromatase and steroid sulfatase 
mRNA levels were measured in breast tissues from patients 
with benign and malignant breast disorders using a nested 
Q-PCR assay. The aim was to validate the effectiveness of 
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the method on FNA samples and to provide new insights 
into the roles of the estrogen biosynthesis related enzymes 
in Chinese women with benign and malignant breast disor-
ders. 
1  Materials and methods 
1.1  Patients 
FNA biopsy samples were collected from 74 patients with a 
mean age of 48 years (range 22–74) who presented at the 
Guang An’men and Beijing Friendship hospitals in 2008. 
The patients were diagnosed with breast cancer or with be-
nign disorders based on a pathohistological examination 
independently evaluated by two pathologists. At biopsy, 
none of the patients received treatment for any breast dis-
eases. Clinical data were obtained at the time of examina-
tion. 
Research protocols for this study were approved by the 
Ethics Committee at Guang An’men Hospital, affiliated to 
the China Academy of Chinese Medical Sciences. 
1.2  Preparation of total RNA and cDNA synthesis 
Samples were immediately placed in Qiagen RNAlater 
RNA Stabilization Reagent until total RNA extraction was 
performed. Total RNA was extracted from specimens fol-
lowing Bio-Rad PureZol RNA Isolation Reagent protocol. 
A MMLV Reverse Transcription kit (Invitrogen Co., Carls-
bad, CA, USA) was used to synthesize cDNA. Because of 
the small amount of tissue that could be obtained and based 
on our experience, a third of the total RNA was used for 
reverse transcription and RNA concentration determination 
was omitted. 
1.3  Quantitation of aromatase, steroid sulfatase and 
estrogen receptor (ER) α mRNAs 
Nested two-step PCR reactions were performed using the 
Light Cycler 480 System (Roche Diagnostics GmbH, 
Mannheim, Germany). For the first PCR, a master-mix was 
prepared on ice with 10×PCR buffer, 0.6 μL of 10 mmol/L 
dNTP mix (10 mmol/L each of dATP, dGTP, dCTP and 
dTTP), 1.6 μL of 10 mmol/L primer (Table 1), 1 unit of 
Qiagen Hot Star Taq DNA polymerase, and 1.2 μL of the 
cDNA template was added to 40 μL of the PCR master-mix. 
The thermal cycling conditions comprised an initial dena-
turation step at 95°C for 15 min and 20 cycles at 95°C for  
1 min, 54°C for 40 s and 72°C for 30 s.  
The second step of the nested Q-PCR and non-nested 
Q-PCR was carried out with the SYBR Green PCR Master 
Mix kit (Applied Biosystems, USA) using the reaction con-
ditions according to the manufacturer’s instructions. An 
aliquot of 0.5 μL of the first PCR product was used as tem-
plate. The primers used are listed in Table 1. 
Relative mRNA expression levels were determined from 
the amount of TBP mRNA which served as a normalizing 
gene. Relative mRNA expression (N) was calculated as 
N=2−Ct, where Ct=Cttarget−Ctreference and Ct is the threshold 
value during the amplification process. 
1.4  Statistical analysis 
The quantity of relative mRNA expression of the samples 
showed non-normal distribution, so rank-sum tests were 
used to examine the relationship between enzyme mRNA 
Table 1  Oligonucleotide primer and sequences used in the PCR 




































ERα 5′-CCACCAACCAGTGCACCATT-3′ 108 
5′-GGTCTTTTCGTATCCCACCTTTC-3′ 
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levels and the clinical parameters of the patients. The corre-
lation between the enzymes and the ER mRNA expression 
levels was assessed according to the Spearman rank correla-
tion test. The proportional hazards model was used for the 
multivariate analysis. Statistical significance was assumed 
for P < 0.05. 
2  Results 
2.1  Characteristics of the patients 
All of the collected samples were divided into two catego-
ries: cancer group (36 cases) and non-cancer group (38 cas-
es). Clinical characteristics are summarized in Table 2. 
2.2  Validation of the nested Q-PCR assay for FNA 
sample 
The mRNA expression of aromatase and steroid sulfatase 
was detected in all the collected FNA samples (74 cases) 
using both the nested and non-nest Q-PCR. To determine  






Age (years)   
≤45 10 19 
>45 & ≤55 12 13 
>55 14 6 
Menopausal   
Pre-menopausal 18 31 
Post-menopausal 18 7 
Disease status   
Ductal carcinoma 32 – 
Adenocarcinoma and others 4 – 
Ductal hyperplasia – 24 
Adenoma – 11 
Others – 3 
 
the reproducibility and sensitivity of the methods, the aro-
matase and the TBP housekeeping genes in each sample 
were measured 3 times on different occasions with both 
methods. Based on the Ct value for each sample during the 
amplification process, all the samples were assigned a Ct 
value for each of the method and the coefficient of variation 
(CV) was calculated for each sample. All 74 samples were 
successfully amplified with the nested Q-PCR assay, and 71 
of the 74 samples were successfully amplified with the 
non-nested Q-PCR assay. For each method, the mean of all 
the CV (%) values was calculated. The mean CV (%) values 
for the nested and non-nested Q-PCR assays were 2.03±0.9 
and 2.25±1.5 respectively. Although the difference in the 
CVs (%) was not significant (P=0.746), for 3 FNA samples 
with trace cells, the nested Q-PCR showed higher sensitivi-
ty compared than the non-nested Q-PCR assay.  
2.3  Comparison of aromatase and steroid sulfatase 
mRNA expression in cancer and non-cancer patients 
As seen in Table 3, aromatase and steroid sulfatase mRNA 
expression levels were analyzed and all patients were cate-
gorized according to the level of enzyme mRNA expression. 
The enzyme expression levels were compared with the 
clinical characteristics of the patients. Since mRNA expres-
sion quantity data followed a non-normal distribution, the 
median, minimum and maximum values in each stratum 
were calculated. The rank-sum tests showed that there were 
no significant differences in the correlation of aromatase or 
sulfatase expression with age (P=0.856 and P=0.569, re-
spectively). However, although the differences in the aro-
matase mRNA expression level for different age groups 
were not statistically significant, a trend which showed a 
growing proportion of samples in the higher age groups 
with higher expression level of enzyme mRNA could be 
seen. The mRNA expression level of aromatase correlated 
with postmenopausal women (P=0.048), but there was no 
correlation between steroid sulfatase expression and meno-
pausal status (P=0.529). 
The aromatase and steroid sulfatase mRNA expression  
Table 3  Patients characteristics and mRNA expression of aromatase and steroid sulfatase in all patients with rank-sum tests 
Characteristics 
Patients mRNA expression 
Aromatasea) Steroid sulfataseb) 
Median (min–max) P valuec) Median (min–max) P valuec) 
Age (years)   0.856  0.569 
≤45 2.84 (0.00–68.87)  019(0.00–0.66)  
>45 & ≤55 2.84 (0.00–115.02)  0.13(0.10–2.22)  
>55 2.78 (0.16–201.66)  0.19(0.03–0.41)  
Menopausal   0.048  0.529 
Pre-menopausal 1.62 (0.00–115.02)  0.14(0.00–0.66)  
Post-menopausal 5.64 (0.02–201.66)  0.16(0.03–2.22)  
a) Aromatase mRNA expression level was calculated by using the equation: N×1000, N = 2−Ct; b) steroid sulfatase mRNA expression level was equal to 
N, N = 2−Ct; c) 95% CI, confidence interval. 
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levels for the cancer and non-cancer patients were analyzed 
(Table 4). For the cancer group, the median of the aroma-
tase mRNA expression level was 7.92, compared with 0.44 
in the non-cancer group. Aromatase expression was signifi-
cantly higher in the cancer group than in the non-cancer 
group (P < 0.001). When stratified on menopausal status, no 
difference in aromatase expression levels was observed 
when pre- and post-menopausal patients were compared. 
There was also no significant difference in steroid sulfatase 
expression levels between the pre- and post-menopausal 
patients. The relative mRNA expression levels of aromatase 
and steroid sulfatase in the cancer (malignant) and non- 
cancer groups (benign) are shown in Figure 1. The aroma-
tase relative expression levels differed in benign versus ma-
lignant samples although an overlap existed between the 
two groups (Figure 1(a)). No significant difference was seen 
in the distribution of steroid sulfatase mRNA expression 
levels between the malignant and benign groups (Figure 
1(b)). 
Correlation analysis between the ERα and enzymes 
mRNA expression levels was also conducted. The Spear-
man rank correlation test found no correlation between ERα 
and aromatase (rs = –0.04, P=0.77) and steroid sulfatase (rs 
=–0.15, P=0.38) expression levels. 
Because the mean age of the patients in the cancer group 
(52.7±9.8) was higher than in the non-cancer group (44.3± 
10.7), we used multivariate analysis to analyze age, meno-
pausal status and enzyme mRNA expression levels in the 
two groups. Multivariate analysis revealed that age and 
aromatase mRNA expression were significantly related to 
the presence of breast cancer (P=0.04 and P=0.00, respec-
tively); menopausal status and steroid sulfatase mRNA ex-
pression level were not associated with breast cancer. 
3  Discussion 
FNA is a breast epithelial sampling technology that pro-
vides a new opportunity for breast molecular studies in 
asymptomatic women [9,10]. As only a few cells of breast 
tissue samples can be obtained by FNA [7], a highly sensi-
tive method for detecting mRNA in the breast tissue aspi-
rates is critical. A sensitive nested Q-PCR developed by us 
[8] and common non-nested Q-PCR were compared using  
Table 4  mRNA expression level of aromatase and steroid sulfatase in cancer and non-cancer group with menopausal status 
  
Cancer group (n) 
P valuea) 
Non-cancer group (n) 
P valuea) 
Median (min–max) Median (min–max) 
Aromataseb) 
Menopausal   0.602   0.596 
Pre-menopausal 7.24 (0.01–68.87)  0.47 (0.00–115.02)  
Post-menopausal 8.00 (0.58–201.66)  0.20 (0.02–3.09)  
Total 7.92 (0.01–201.66)  0.44 (0.00–115.02) 0.000 
Steroid sulfatasec) 
Menopausal  0.734  0.632 
Pre-menopausal 0.17 (0.02–0.66)  0.14 (0.00–0.54)  
Post-menopausal 0.17 (0.03–2.22)  0.15 (0.01–0.65)  
Total 0.17 (0.02–2.22)  0.14 (0.00–0.65) 0.274 
a) 95% CI, confidence interval; b) aromatase mRNA expression level was calculated by using the equation: N×1000, N = 2−Ct; c) steroid sulfatase mRNA 




Figure 1  Relative mRNA expression levels of aromatase and steroid sulfatase in cancer (malignant) and non-cancer groups (benign). (a) Aromatase 
mRNA expression levels in benign and malignant breast cancer. The relative mRNA expression levels were calculated as N×1000. (b) Steroid sulfatase 
mRNA expression levels of benign and malignant breast cancer. The relative mRNA expression levels were equal to N. N=2−Ct, where Ct=Cttarget–Ctreference 
and Ct is the threshold value during the amplification process. 
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the FNA samples. Our data showed that samples containing 
trace mRNA were easily detected with nested Q-PCR. 
Overall there was no obvious difference between the nested 
and non-nested Q-PCR method; both effectively amplified 
the aromatase mRNA. This experiment revealed that, for 
estrogen related enzyme expression studies, the FNA sam-
ples were easy to handle. This was in contrast to the results 
with ductal lavage fluid samples which contain too few cells 
for valid assay. This study provided additional support for 
the application of our methodology. 
Breast cancer is the major cause of cancer deaths for 
women in the world [11]. The incidence-age curves of 
breast cancer around the world are significantly different. In 
China and Japan, the peak age of breast cancer incidence is 
about 40–50 years and cancer incidence is associated with 
increased mortality, while in the United States and other 
western countries, the incidence continuously increases with 
age and the morality rate is decreasing [3,12,13]. The un-
derlying reasons for the different incidence-age curves are 
not clear. Many epidemiological and experimental studies 
showed that estrogens were the fuel behind the aetiology of 
breast cancer and about 60% of pre-menopausal and 75% of 
post-menopausal patients with breast cancer had estrogen 
dependent carcinomas [14]. Estrogen synthesis, metabolism, 
and signaling are considered to be the basic carcinogenic 
mechanism of breast cancer [15]. The results of this study 
showed that changes in the peak aromatase and steroid sul-
fatase mRNA levels had no correlation with the inci-
dence-age curve in China. Therefore, the different inci-
dence-age curves reported in East Asia and western coun-
tries need to be studied further. 
Cancer tissue and adjacent tissue are generally used in 
tumor related research. Using Q-PCR analysis, it was con-
firmed that the adipose stromal cells surrounding cancer 
cells contained higher levels of aromatase mRNA than adi-
pose stromal cells in non-cancerous areas [16,17]. It was 
demonstrated that the in situ overexpression of aromatase 
played an important role in breast tumor promotion [18–20]. 
In the present study, we collected specimens from patients 
who underwent FNA cytological test. Therefore, the non- 
cancer specimens we obtained were not tissues neighboring 
cancer cells, but absolutely “normal” tissue. This allowed us 
to reliably determine the characteristics of pre-malignant 
tissue. Most non-cancer patients had breast ductal hyper-
plasia and some of them had pre-cancerous lesions with 
varying morphology. Our results showed that, in general, 
the non-cancer samples expressed lower mRNA levels of 
aromatase than the cancer samples; however, some non- 
cancer specimens did have very high aromatase expression 
levels (Figure 1). Breast cancer is the result of a continuous 
series of events. A possible model of its progression shows 
its evolution from proliferative disease without atypia 
(PDWA) to atypical ductal hyperplasia (ADH), from ADH 
to ductal carcinoma in situ (DCIS), from DCIS to invasive 
carcinoma, and finally to invasive ductal carcinoma [20]. In 
this progression estradiol (E2) has been considered as one 
of the most risk factors [21,22]. Investigators have shown 
that aromatase mRNA expression levels were higher in 
breast cancer patients who developed local recurrence and 
distal metastasis [23]. The high levels of aromatase mRNA 
expression in non-cancer patients, therefore, gave us a hint 
of what might happen to the benign breast cancers. Bi-
omarkers for risk assessment using an intraductal approach 
have been discussed recently [24–26] and Q-PCR provides 
a clinically acceptable technique for biomarker research. 
This offers a way to verify whether the aromatase level in 
NAF atypia is a predictive factor for future clinical man-
agement. A cohort study of the FNA benign breast patients 
is needed to confirm it. 
Our research showed that the aromatase mRNA expres-
sion level in post-menopausal women was generally high 
compared with the level in pre-menopausal women; a simi-
lar association was not observed from the steroid sulfatase 
expression level (P=0.529). This result might be because of 
the small specimen number that was available for the ster-
oid sulfatase test. The enzyme expression levels were ana-
lyzed in the cancer and non-cancer groups; surprisingly, we 
found no relationship between steroid sulfatase mRNA ex-
pression levels and cancer incidence, contradicting the re-
sults of other studies [27,28]. It is possible that race or dif-
ferent sample collecting methods may explain this differ-
ence. 
Estrogen action is mediated by ER receptors and the 
presence of ERα has been implicated in a better prognosis 
for response to hormonal therapy [29]. ER status was absent 
in the clinical parameters because the FNA patients with 
benign lesions went home without surgery. The ERα mRNA 
expression level was analyzed to verify the association be-
tween the enzymes and ER mRNA expression. Our results 
showed no linear relationship between the ER and enzymes 
mRNA expression levels. 
The present study had several drawbacks. Patient num-
bers were small and the ages of the patients in the cancer 
and non-cancer groups did not match; in particular, there 
was a lack of post-menopausal women in the non-cancer 
group. Therefore, the conclusions from this study need fur-
ther verification in a larger sample population. 
In summary, we tested aromatase and steroid sulfatase 
mRNA expression levels of FNA specimens by a nested 
Q-PCR assay. Our results suggested that both nested and 
non-nested Q-PCR assay were effective methods for ana-
lyzing breast FNA samples. We found that age and aroma-
tase mRNA expression levels were two independent risk 
factors for breast cancer. 
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